Registry for adults with ADPKD starting tolvaptan
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This registry study collects information about adults with autosomal dominant polycystic kidney disease (ADPKD) who are starting or already taking tolvaptan. It may help researchers understand how tolvaptan is used in real life and what outcomes look like over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 18
- You have ADPKD (adult polycystic kidney disease) confirmed by your family history and kidney cysts, or diagnosed by your doctor
- You are coming to this center because you need tolvaptan, plan to start it, or have already started it
- You must be able to give informed consent (understand and agree to participate)
- You should not already be in kidney failure that requires dialysis or another “renal replacement therapy”
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps people with ADPKD and moderate kidney damage decide together with their doctor whether to start a treatment called tolvaptan. It tests a shared decision-making tool to see if it helps patients understand their options better.
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Hear when a new ADPKD (Autosomal Dominant Polycystic Kidney Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.